痙縮 - 市場考察、疫学、市場予測（2032年）

主要7市場（米国・ドイツ・フランス・イタリア・スペイン・英国・日本）の痙縮の市場規模は、2021年に最大9億400万米ドルが観測されました。

当レポートでは、痙縮の主要7市場について調査分析し、市場規模と予測、現在の治療法と新薬の情報などを提供しています。

目次

第1章 主要考察

第2章 レポートのイントロダクション

第3章 痙縮市場の概要

• 主要7市場の痙縮の市場シェア分布：治療法別（2019年）
• 主要7市場の痙縮の市場シェア分布：治療法別（2032年）

第4章 痙縮：将来の見通し

第5章 痙縮のエグゼクティブサマリー

第6章 主な出来事

第7章 疾患の背景と概要

• イントロダクション
• 臨床症状
• 病態生理学
• 症状
• 診断

第8章 治療と管理

• 痙縮の予防
• 痙縮の合併症
• 治療と管理のガイドライン

第9章 調査手法

第10章 疫学と患者数

• 主な調査結果
• 前提条件と根拠
• 疫学シナリオ：主要7市場
  • 主要7市場の痙縮の総症例数
• 米国
• 欧州5ヶ国
• 日本

第11章 ペイシェントジャーニー

第12章 上市済みの製品

第13章 新たな治療法

第14章 痙縮の主要7市場の分析

• 主な調査結果
• 市場の見通し
• 主な市場の予測の前提条件
• 主要7市場の痙縮の市場規模（2019年～2032年）
• 主要7市場の痙縮の市場規模：治療法別（2019年～2032年）
• 米国の市場規模
• 欧州5ヶ国の市場規模
• 日本

第15章 市場参入と償還

第16章 KOLの見解

第17章 アンメットニーズ

第18章 SWOT分析

第19章 付録

第20章 DelveInsightのサービス内容

第21章 免責事項

第22章 DelveInsightについて

List of Tables

• Table 1: Summary of Spasticity Market, and Epidemiology (2019-2032)
• Table 2: Key Events
• Table 3: Total Cases of Spasticity in the 7MM (2019-2032)
• Table 4: Total Cases of Spasticity in the United States (2019-2032)
• Table 5: Indication-specific Cases of Spasticity in the United States (2019-2032)
• Table 6: Severity-specific Cases of Spasticity in the United States (2019-2032)
• Table 7: Total Cases of Spasticity in the EU5, in in '000 (2019-2032)
• Table 8: Indication-specific Cases of Spasticity in the EU5 (2019-2032)
• Table 9: Severity-specific Cases of Spasticity in the EU5 (2019-2032)
• Table 10: Total Cases of Spasticity in Japan (2019-2032)
• Table 11: Indication-specific Cases of Spasticity in Japan (2019-2032)
• Table 12: Total Cases of Spasticity by Indications in Japan (2019-2032)
• Table 13: Comparison of marketed drugs
• Table 14: DYSPORT Clinical Trial Description, 2022
• Table 15: XEOMIN Clinical Trial Description, 2022
• Table 16: BOTOX Clinical Trial Description, 2022
• Table 17: SATIVEX (nabiximols), Clinical Trial Description, 2022
• Table 18: GABLOFEN (baclofen injection), Clinical Trial Description, 2022
• Table 19: Comparison of Emerging Drugs
• Table 20: Arbaclofen ER, Clinical Trial Description, 2022
• Table 21: Key Market Forecast Assumptions for Arbaclofen ER
• Table 22: Market Size of Spasticity in the 7MM in USD Million (2019-2032)
• Table 23: Market Size of Spasticity by Therapies in the 7MM in USD Million (2019-2032)
• Table 24: Market Size of Spasticity in the United States, USD Million (2019-2032)
• Table 25: Market Size of Spasticity by Therapies in the United States in USD Million (2019-2032)
• Table 26: Market Size of Spasticity in the EU5, USD Million (2019-2032)
• Table 27: Market Size of Spasticity by Therapies in the EU5 in USD Million (2019-2032)
• Table 28: Japan Market Size of Spasticity, in USD Million (2019-2032)
• Table 29: Market Size of Spasticity by Therapies in Japan in USD Million (2019-2032)

List of Figures

• Figure 1: Total Cases of Spasticity in the 7MM (2019-2032)
• Figure 2: Total Cases of Spasticity in the United States (2019-2032)
• Figure 3: Indication-specific Cases of Spasticity in the United States (2019-2032)
• Figure 4: Severity-specific Cases of Spasticity in the United States (2019-2032)
• Figure 5: Total Cases of Spasticity in the EU5 (2019-2032)
• Figure 6: Indication-specific Cases of Spasticity in the EU5 (2019-2032)
• Figure 7: Severity-specific Cases of Spasticity in the EU5 (2019-2032)
• Figure 8: Total Cases of Spasticity in Japan (2019-2032)
• Figure 9: Indication-specific Cases of Spasticity in Japan (2019-2032)
• Figure 10: Total Cases of Spasticity by Indications in Japan (2019-2032)
• Figure 11: Patient Journey
• Figure 12: Market Size of Spasticity in the 7MM in USD Million (2019-2032)
• Figure 13: Market Size of Spasticity by Therapies in the 7MM in USD Million (2019-2032)
• Figure 14: Market Size of Spasticity in the United States, USD Million (2019-2032)
• Figure 15: Total Market size of Spasticity by Therapies in the United States, USD Million (2019-2032)
• Figure 16: Market Size of Spasticity in the EU5, USD Million (2019-2032)
• Figure 17: Total Market size of Spasticity by Therapies in the EU5, USD Million (2019-2032)
• Figure 18: Market Size of Spasticity in Japan, USD Million (2019-2032)
• Figure 19: Market Size of Spasticity by Therapies in Japan, USD Million (2019-2032)
• Figure 20: Unmet Needs

DelveInsight's 'Spasticity - Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of spasticity historical and forecasted epidemiology as well as the spasticity market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The spasticity market report provides current treatment practices, emerging drugs, and market share of individual therapies, current and forecasted 7MM spasticity market size. The report also covers a descriptive overview of Spasticity, SWOT analysis, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032.

Spasticity Understanding

Spasticity Overview

Spasticity is a condition in which there is an abnormal increase in muscle tone or muscle stiffness, which might interfere with movement and speech or be associated with discomfort or pain. Spasticity may be associated with spinal cord injury, multiple sclerosis, cerebral palsy, stroke, brain or head trauma, amyotrophic lateral sclerosis, hereditary spastic paraplegias, and metabolic diseases such as adrenoleukodystrophy, phenylketonuria, and Krabbe disease. Symptoms may include hypertonicity (increased muscle tone), clonus (a series of rapid muscle contractions), exaggerated deep tendon reflexes, muscle spasms, scissoring (involuntary crossing of the legs), and fixed joints (contractures). The degree of spasticity varies from mild muscle stiffness to severe, painful, and uncontrollable muscle spasms. Spasticity can interfere with rehabilitation in patients with certain disorders and often interferes with daily activities

Continued in the report…

Spasticity Pathophysiology

The pathophysiologic basis of spasticity is incompletely understood. Polysynaptic responses may be involved in the spinal cord-mediated spasticity, while enhanced excitability of monosynaptic pathways is involved in cortically mediated spasticity. Spasticity-related changes in muscle tone probably result from alterations in the balance of inputs from reticulospinal and other descending pathways to the motor and interneuronal circuits of the spinal cord, along with the absence of an intact corticospinal system. Loss of descending tonic or phasic excitatory and inhibitory inputs to the spinal motor apparatus, alterations in the segmental balance of excitatory and inhibitory control, denervation super sensitivity, and neuronal sprouting may be observed.

Continued in the report…

Spasticity Clinical Presentation

Spasticity in cerebral palsy

In a person with cerebral palsy (CP), brain damage is in the area that controls muscle tone and movement of the arms and legs. Therefore, the brains of people with cerebral palsy cannot influence the number of flexibility muscles should have. The command from the muscle itself dominates the spinal cord and results in muscles that are too tense or spastic. The patients born with cerebral palsy do not have deformities of the extremities present at birth but develop them over time. Spasticity of muscles, along with the limitations on stretching and the use of muscles in daily activities, is a major cause of these deformities.

Spasticity in multiple sclerosis

Spasticity is one of the most common symptoms of multiple sclerosis (MS) and is defined as muscle stiffness that is frequently generalized and causes more or less continuous rigidity. It is normally associated with temporary periods of worsening in the form of involuntary muscle spasms, and all the while, muscle function is progressively lost. Spasticity is one of the primary reasons for disability in multiple sclerosis since it is associated with pain, changes in bladder function and sleep, and the inability to walk and perform other movements, including those required for personal hygiene.

Continued in the report…..

Spasticity Epidemiology

The epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Cases of Spasticity, Indication-specific Cases of Spasticity, and Severity-specific Cases of Spasticity scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Key Findings

• In 2021, the total cases of spasticity were ~7,871,000 in the 7MM which are expected to increase by 2032.
• The United States, in 2021, accounted for the highest number of cases of spasticity (~4,756,000 cases). These cases are expected to increase by the year 2032.
• In 2021, Japan accounted for ~823,000 cases of spasticity, which was approximately 10% of the total spasticity cases in 7MM.
• The total number of mild, moderate, and severe spasticity cases in the 7MM was ~1,504,000; ~2,424,000; and ~1,582,000 in 2021.
• In 2021, the total number of spasticity cases due to cerebral palsy, multiple sclerosis, post-stroke, traumatic brain injury, and spinal cord injury were ~533,000; ~499,000; ~689,000; ~472,000; and ~98,000 respectively in the EU5.

Spasticity Drug Chapters

Spasticity Emerging Drugs

Arbaclofen ER: RVL Pharmaceuticals

Arbaclofen ER is an extended-release formulation of arbaclofen, the R isomer of baclofen that leverages the proprietary for osmodex drug delivery system and is being studied for the treatment of spasticity resulting from multiple sclerosis. It acts upstream of the mGluR5 receptor to increase inhibitory neurotransmission. It is the isomer of baclofen which harbors antispastic activity.

Product details in the report…

Spasticity Market Outlook

Spasticity affects a patient's independence in activities of daily living such as hygiene, dressing, self-comfort, ambulation, and sleep. Later it may lead to significant pain, contractures, joint subluxations or dislocations, peripheral neuropathy, and pressure ulcers. Therefore, treating this condition is imperative to improve the quality of life and minimize medical complications. Conversely, spasticity can help patients transfer, stand, ambulate, and maintain muscle bulk.

Various treatments are available for controlling spasticity; nonmedical treatments, including physical, occupational, and complementary and alternative medicine, are effective adjuncts to mainstream oral agents and interventional therapies. While each therapy is efficacious in treating spasticity, the treatments also come with adverse effects. In general, oral agents are more inexpensive in the short term and easier to use, but they have unwanted systemic effects, which can outweigh the potential benefits they may provide. At the same time, these systemic drugs may be better for patients with generalized spasticity.

On the other hand, interventional therapies pose the problem of procedural errors, difficulty finding a trained provider to perform the procedure, and further complications. However, it may provide greater control of spasticity with fewer systemic side effects if patients are compliant and can tolerate the procedures. Although there are effective treatment options for spasticity, there is currently no cure.

Continued in the report…..

Key Findings

• The market size of spasticity in the 7MM was observed to be ~USD 904 million in 2021.
• In 2021, the US has the largest spasticity market size of ~USD 736 million among the 7MM countries.
• Among the EU5 countries, the UK had the highest market size for spasticity in 2021, i.e., ~USD 45 million. The lowest market size was estimated in Spain with ~USD 15 million in 2021.
• In Japan, the market size for spasticity was observed to be ~USD 35 million in 2021.

The United States Market Outlook

This section provides the total spasticity market size and market size by therapies in the United States.

EU5 Market Outlook

The total spasticity market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total spasticity market size and market size by therapies in Japan are provided.

Spasticity Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the spasticity market or expected to get launched in the market during the study period 2019-2032. The analysis covers the spasticity market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, and reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Spasticity Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers detailed information on collaborations, acquisitions, merger, licensing, and patent details for spasticity emerging therapies.

Reimbursement Scenario in Spasticity

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Competitive Intelligence Analysis

We perform competitive market Intelligence analysis of the spasticity market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

• The report covers a descriptive overview of spasticity, explaining its associated indications, and currently available therapies.
• Comprehensive insight has been provided into spasticity epidemiology and treatment.
• Additionally, an all-inclusive account of both the current and emerging therapies for spasticity is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of the spasticity market; historical and forecasted is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM spasticity market.

Report Highlights:

• The robust pipeline with novel MOA and oral ROA, increasing prevalence, and effectiveness of drugs will positively drive the spasticity market.
• The companies and academics are working to assess challenges and seek opportunities that could influence spasticity R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition using spasticity.
• Major players are involved in developing therapies for spasticity. The launch of emerging therapies will significantly impact the spasticity market.
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Spasticity Report Insights

• Patient Population
• Therapeutic Approaches
• Spasticity Pipeline Analysis
• Spasticity Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Spasticity Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Spasticity Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Spasticity Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• SWOT analysis

Key Questions

Market Insights:

• What was the spasticity market share (%) distribution in 2019 and how it would look like in 2032?
• What would be the spasticity total market size as well as market size by therapies across the 7MM during the forecast period (2022-2032)?
• What are the key findings pertaining to the market across the 7MM and which country will have the largest spasticity market size during the forecast period (2022-2032)?
• At what CAGR, the spasticity market is expected to grow at the 7MM level during the forecast period (2022-2032)?
• What would be the spasticity market outlook across the 7MM during the forecast period (2022-2032)?
• What would be the spasticity market growth till 2032 and what will be the resultant market size in the year 2032?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What are the risk, burdens, and unmet needs of spasticity?
• What is the historical spasticity patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
• What would be the forecasted patient pool of spasticity at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to spasticity?
• Out of the above-mentioned countries, which country would have the highest cases of spasticity during the forecast period (2022-2032)?
• At what CAGR are these cases expected to grow across the 7MM during the forecast period (2022-2032)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

• What are the current treatment practices in spasticity along with the approved therapy?
• What are the current treatment guidelines for spasticity?
• What are the spasticity marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
• How many companies are developing therapies for spasticity?
• How many emerging therapies are in the mid-stage and late stages of development for spasticity?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the spasticity therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for spasticity and their status?
• What are the key designations that have been granted for the emerging therapies for spasticity?
• What are the 7MM historical and forecasted market of spasticity?

Reasons to buy:

• The report will help in developing business strategies by understanding trends shaping and driving spasticity.
• To understand the future market competition in the spasticity market and an insightful review of the market.
• Organize sales and marketing efforts by identifying the best opportunities for spasticity in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for the spasticity market.
• To understand the future market competition in the spasticity market.

Table of Contents

1. Key Insights

2. Report Introduction

3. Spasticity Market Overview at a Glance

• 3.1. Market Share (%) Distribution of Spasticity by Therapies in the 7MM in 2019
• 3.2. Market Share (%) Distribution of Spasticity by Therapies in the 7MM in 2032

4. Spasticity: Future Prospects

5. Executive Summary of Spasticity

6. Key events

7. Disease Background and Overview

• 7.1. Introduction
• 7.2. Clinical Presentation
  • 7.2.1. Spasticity in cerebral palsy
  • 7.2.2. Spasticity in multiple sclerosis
  • 7.2.3. Spasticity in traumatic brain injury (TBI)
  • 7.2.4. Spasticity in meningitis
  • 7.2.5. Spasticity in amyotrophic lateral sclerosis (ALS)
  • 7.2.6. Post-stroke spasticity
• 7.3. Pathophysiology
• 7.4. Symptoms
• 7.5. Diagnosis
  • 7.5.1. Clinical assessment
  • 7.5.2. Other diagnostic tests
  • 7.5.3. Severity classification and evaluation scales
  • 7.5.4. Associated conditions and differential diagnosis

8. Treatment and Management

• 8.1.1. Prevention of spasticity
• 8.1.2. Complications of spasticity
• 8.2. Treatment and Management Guidelines
  • 8.2.1. French Recommendations for the Management of Patients with Spasticity in Spinal Cord Injury (2020)
  • 8.2.2. Multiple Sclerosis in Adults: Management (NICE Guideline 2022)
  • 8.2.3. Spasticity in Adults: Management Using Botulinum Toxin: Royal College of Physicians: 2018

9. Methodology

10. Epidemiology and Patient Population

• 10.1. Key Findings
• 10.2. Assumptions and Rationale
• 10.3. Epidemiology Scenario: 7MM
  • 10.3.1. Total Cases of Spasticity in the 7MM
• 10.4. The United States
  • 10.4.1. Total Cases of Spasticity in the United States
  • 10.4.2. Indication-specific Cases of Spasticity in the United States
  • 10.4.3. Severity-specific Cases of Spasticity in the United States
• 10.5. EU5
  • 10.5.1. Total Cases of Spasticity in the EU5
  • 10.5.2. Indication-specific Cases of Spasticity in the EU5
  • 10.5.3. Severity-specific Cases of Spasticity in the EU5
• 10.6. Japan
  • 10.6.1. Total Cases of Spasticity in Japan
  • 10.6.2. Indication-specific Cases of Spasticity in Japan
  • 10.6.3. Severity-specific Cases of Spasticity in Japan

11. Patient Journey

12. Marketed Products

• 12.1. Key-cross
• 12.2. DYSPORT: Ipsen Biopharmaceuticals, Inc.
  • 12.2.1. Product description
  • 12.2.2. Regulatory milestones
  • 12.2.3. Other developmental activities
  • 12.2.4. Clinical developmental activities
  • 12.2.5. Safety and efficacy
• 12.3. XEOMIN: Merz Pharmaceuticals
  • 12.3.1. Product description
  • 12.3.2. Regulatory milestones
  • 12.3.3. Other developmental activities
  • 12.3.4. Clinical developmental activities
  • 12.3.5. Safety and efficacy
• 12.4. BOTOX (onabotulinumtoxinA): Allergan, Inc
  • 12.4.1. Product description
  • 12.4.2. Regulatory milestones
  • 12.4.3. Other developmental activities
  • 12.4.4. Clinical developmental activities
  • 12.4.5. Safety and efficacy
• 12.5. SATIVEX (nabiximols): Jazz Pharmaceuticals
  • 12.5.1. Product description
  • 12.5.2. Regulatory milestones
  • 12.5.3. Other developmental activities
  • 12.5.4. Clinical developmental activities
  • 12.5.5. Safety and efficacy
• 12.6. OZOBAX (baclofen oral solution): Metacel Pharmaceuticals
  • 12.6.1. Product description
  • 12.6.2. Regulatory milestones
  • 12.6.3. Other developmental activities
  • 12.6.4. Clinical developmental activities
  • 12.6.5. Safety and efficacy
• 12.7. GABLOFEN (baclofen injection): Piramal
  • 12.7.1. Product description
  • 12.7.2. Regulatory milestones
  • 12.7.3. Other developmental activities
  • 12.7.4. Clinical developmental activities
  • 12.7.5. Safety and efficacy
• 12.8. LYVISPAH (baclofen oral granules): Amneal Pharmaceuticals
  • 12.8.1. Product description
  • 12.8.2. Regulatory milestones
  • 12.8.3. Other developmental activities
  • 12.8.4. Clinical developmental activities
  • 12.8.5. Safety and efficacy
• 12.9. FLEQSUVY (baclofen oral suspension): Azurity
  • 12.9.1. Product description
  • 12.9.2. Regulatory milestones
  • 12.9.3. Other developmental activities
  • 12.9.4. Clinical developmental activities
  • 12.9.5. Safety and efficacy
• 12.10. GABALON: Daiichi Pharmaceutical Co., Ltd.
  • 12.10.1. Product description
  • 12.10.2. Regulatory milestones
  • 12.10.3. Other developmental activities

13. Emerging Therapies

• 13.1. Key Cross Competition
• 13.2. Arbaclofen ER: RVL Pharmaceuticals (previously known as Osmotica Pharmaceuticals)
  • 13.2.1. Product description
  • 13.2.2. Other developmental activity
  • 13.2.3. Clinical developmental activities
  • 13.2.4. Safety and efficacy

14. Spasticity Seven Major Market Analysis

• 14.1. Key Findings
• 14.2. Market Outlook
• 14.3. Key Market Forecast Assumptions
• 14.4. Market Size of Spasticity in the 7MM (2019-2032)
• 14.5. Market Size of Spasticity by Therapies in the 7MM (2019-2032)
• 14.6. The United States Market Size
  • 14.6.1. Total Market size of Spasticity in the United States
  • 14.6.2. Total Market size of Spasticity by Therapies in the United States
• 14.7. EU5 Market Size
  • 14.7.1. Total Market size of Spasticity in the EU5
  • 14.7.2. Total Market size of Spasticity by Therapies in the EU5
• 14.8. Japan
  • 14.8.1. Total Market size of Spasticity in Japan
  • 14.8.2. Total Market size of Spasticity by Therapies in Japan

15. Market Access and Reimbursement

• 15.1. Reimbursement

16. KOL Views

17. Unmet Needs

18. SWOT Analysis

19. Appendix

• 19.1. Report Methodology
• 19.2. Bibliography

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight